Onsite PTSD Treatment to Improve MOUD Outcomes (OPTIMO): a hybrid Type 1 effectiveness-implementation trial of harm reduction PTSD care at syringe service programs

Medicine & Life Sciences

1. Post-Traumatic Stress Disorders 100%
2. Opioid Analgesics 93%
3. Harm Reduction 79%
4. Syringes 63%
5. Pharmaceutical Preparations 25%
6. CPT protocol 20%
7. Telemedicine 17%
8. Therapeutics 12%
9. Buprenorphine 9%
10. Delivery of Health Care 9%
11. Health Care Process Assessment 9%
12. Emotional Regulation 9%
13. Methadone 8%
14. Centers for Disease Control and Prevention (U.S.) 8%
15. Focus Groups 7%
16. HIV Infections 6%
17. Substance-Related Disorders 6%
18. Organizations 6%
19. Population 6%
20. Mental Health 6%
21. Maintenance 5%